Jubilant Pharmova Limited (JUBLPHARMA.BO)
INR 881.1
(-0.37%)
INR 881.1
(-0.37%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 115.48 Billion INR | 3.51% |
| 2022 | 111.56 Billion INR | 11.67% |
| 2021 | 99.9 Billion INR | 12.03% |
| 2020 | 89.18 Billion INR | -28.78% |
| 2019 | 125.21 Billion INR | 9.18% |
| 2018 | 114.68 Billion INR | 19.24% |
| 2017 | 96.17 Billion INR | 6.38% |
| 2016 | 90.4 Billion INR | 2.45% |
| 2015 | 88.24 Billion INR | 3.37% |
| 2014 | 85.36 Billion INR | -3.69% |
| 2013 | 88.63 Billion INR | 5.89% |
| 2012 | 83.7 Billion INR | 7.69% |
| 2011 | 77.73 Billion INR | 2.66% |
| 2010 | 75.71 Billion INR | 10.26% |
| 2009 | 68.67 Billion INR | 1.55% |
| 2008 | 67.62 Billion INR | 60.64% |
| 2007 | 42.09 Billion INR | 29.79% |
| 2006 | 32.43 Billion INR | 57.52% |
| 2005 | 20.58 Billion INR | 63.08% |
| 2004 | 12.62 Billion INR | 45.18% |
| 2003 | 8.69 Billion INR | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q2 | 119.24 Billion INR | 0.0% |
| 2024 Q1 | - INR | -100.0% |
| 2023 Q3 | - INR | -100.0% |
| 2023 Q1 | - INR | -100.0% |
| 2023 Q4 | 115.48 Billion INR | 0.0% |
| 2023 Q2 | 113.99 Billion INR | 0.0% |
| 2023 FY | 115.48 Billion INR | 3.51% |
| 2022 Q2 | 107.04 Billion INR | 0.0% |
| 2022 Q4 | 111.56 Billion INR | 0.0% |
| 2022 FY | 111.56 Billion INR | 11.67% |
| 2022 Q1 | - INR | -100.0% |
| 2022 Q3 | - INR | -100.0% |
| 2021 Q1 | - INR | -100.0% |
| 2021 Q2 | 94.82 Billion INR | 0.0% |
| 2021 Q3 | - INR | -100.0% |
| 2021 Q4 | 99.9 Billion INR | 0.0% |
| 2021 FY | 99.9 Billion INR | 12.03% |
| 2020 Q1 | - INR | -100.0% |
| 2020 FY | 89.18 Billion INR | -28.78% |
| 2020 Q3 | - INR | -100.0% |
| 2020 Q4 | 89.18 Billion INR | 0.0% |
| 2020 Q2 | 123.86 Billion INR | 0.0% |
| 2019 Q2 | 118.92 Billion INR | 0.0% |
| 2019 FY | 125.21 Billion INR | 9.18% |
| 2019 Q1 | - INR | -100.0% |
| 2019 Q3 | - INR | -100.0% |
| 2019 Q4 | 125.21 Billion INR | 0.0% |
| 2018 FY | 114.68 Billion INR | 19.24% |
| 2018 Q4 | 114.68 Billion INR | 0.0% |
| 2018 Q3 | - INR | -100.0% |
| 2018 Q2 | 106.66 Billion INR | 0.0% |
| 2018 Q1 | - INR | -100.0% |
| 2017 FY | 96.17 Billion INR | 6.38% |
| 2017 Q2 | 94.03 Billion INR | 0.0% |
| 2017 Q3 | - INR | -100.0% |
| 2017 Q4 | 96.17 Billion INR | 0.0% |
| 2017 Q1 | - INR | -100.0% |
| 2016 FY | 90.4 Billion INR | 2.45% |
| 2016 Q2 | 88.57 Billion INR | 0.0% |
| 2016 Q1 | - INR | -100.0% |
| 2016 Q4 | 90.4 Billion INR | 0.0% |
| 2016 Q3 | - INR | -100.0% |
| 2015 Q3 | - INR | -100.0% |
| 2015 FY | 88.24 Billion INR | 3.37% |
| 2015 Q4 | 88.24 Billion INR | 0.0% |
| 2015 Q2 | 88.24 Billion INR | 0.0% |
| 2015 Q1 | - INR | -100.0% |
| 2014 Q4 | 85.36 Billion INR | 0.0% |
| 2014 FY | 85.36 Billion INR | -3.69% |
| 2014 Q2 | 89.22 Billion INR | 0.0% |
| 2014 Q1 | - INR | -100.0% |
| 2014 Q3 | - INR | -100.0% |
| 2013 Q4 | 88.63 Billion INR | 0.0% |
| 2013 FY | 88.63 Billion INR | 5.89% |
| 2013 Q3 | - INR | -100.0% |
| 2013 Q1 | - INR | -100.0% |
| 2013 Q2 | 88.41 Billion INR | 0.0% |
| 2012 Q4 | 83.7 Billion INR | 0.0% |
| 2012 FY | 83.7 Billion INR | 7.69% |
| 2011 FY | 77.73 Billion INR | 2.66% |
| 2011 Q4 | 77.73 Billion INR | 0.0% |
| 2010 FY | 75.71 Billion INR | 10.26% |
| 2009 FY | 68.67 Billion INR | 1.55% |
| 2008 FY | 67.62 Billion INR | 60.64% |
| 2007 FY | 42.09 Billion INR | 29.79% |
| 2006 FY | 32.43 Billion INR | 57.52% |
| 2005 FY | 20.58 Billion INR | 63.08% |
| 2004 FY | 12.62 Billion INR | 45.18% |
| 2003 FY | 8.69 Billion INR | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Alembic Pharmaceuticals Limited | 64.45 Billion INR | -79.169% |
| Aurobindo Pharma Limited | 450.71 Billion INR | 74.377% |
| Glenmark Life Sciences Limited | 28.5 Billion INR | -305.152% |
| Granules India Limited | 55.2 Billion INR | -109.175% |
| Indoco Remedies Limited | 21.44 Billion INR | -438.459% |
| Achyut Healthcare Limited | 309.52 Million INR | -37210.757% |
| Ajanta Pharma Limited | 46.38 Billion INR | -148.976% |
| Alkem Laboratories Limited | 155.74 Billion INR | 25.852% |
| Alpa Laboratories Limited | 1.82 Billion INR | -6223.728% |
| Brooks Laboratories Limited | 904.45 Million INR | -12668.477% |
| AstraZeneca Pharma India Limited | 10.78 Billion INR | -971.261% |
| Bajaj HealthCare Limited | 7.65 Billion INR | -1409.356% |
| Bliss GVS Pharma Limited | 12.13 Billion INR | -851.38% |
| Dr. Reddy's Laboratories Limited | 387.51 Billion INR | 70.199% |
| Eris Lifesciences Limited | 70.48 Billion INR | -63.836% |
| FDC Limited | 24.68 Billion INR | -367.912% |
| Glenmark Pharmaceuticals Limited | 143.58 Billion INR | 19.571% |
| Gufic Biosciences Limited | 10.92 Billion INR | -957.031% |
| Ind-Swift Laboratories Limited | 11.65 Billion INR | -891.197% |
| Ipca Laboratories Limited | 111.01 Billion INR | -4.029% |
| Jagsonpal Pharmaceuticals Limited | 2.17 Billion INR | -5219.977% |
| Krebs Biochemicals & Industries Limited | 1.78 Billion INR | -6381.56% |
| Lasa Supergenerics Limited | 1.5 Billion INR | -7554.669% |
| Laurus Labs Limited | 83.87 Billion INR | -37.695% |
| Lupin Limited | 239.97 Billion INR | 51.876% |
| Mankind Pharma Limited | 119.63 Billion INR | 3.467% |
| Medicamen Biotech Limited | 2.94 Billion INR | -3821.094% |
| Medico Remedies Limited | 961.95 Million INR | -11905.264% |
| Megasoft Limited | 3.65 Billion INR | -3056.193% |
| NATCO Pharma Limited | 69.06 Billion INR | -67.217% |
| Piramal Pharma Limited | 153.11 Billion INR | 24.578% |
| RPG Life Sciences Limited | 5.12 Billion INR | -2151.74% |
| Sigachi Industries Limited | 6.94 Billion INR | -1563.674% |
| Sun Pharmaceutical Industries Limited | 854.62 Billion INR | 86.487% |
| Suven Pharmaceuticals Limited | 22.54 Billion INR | -412.336% |
| Syncom Formulations (India) Limited | 4.04 Billion INR | -2753.85% |
| Unichem Laboratories Limited | 31.69 Billion INR | -264.381% |
| Wanbury Limited | 3.43 Billion INR | -3262.076% |
| Windlas Biotech Limited | 6.26 Billion INR | -1744.201% |
| ZIM Laboratories Limited | 4.46 Billion INR | -2484.585% |
| Zydus Lifesciences Limited | 292.8 Billion INR | 60.559% |
| Sun Pharma Advanced Research Company Limited | 5.15 Billion INR | -2142.253% |
| Divi's Laboratories Limited | 154.7 Billion INR | 25.349% |
| Hester Biosciences Limited | 6.62 Billion INR | -1643.572% |
| Procter & Gamble Health Limited | 7.94 Billion INR | -1353.812% |
| Amrutanjan Health Care Limited | 3.66 Billion INR | -3047.839% |
| Bal Pharma Limited | 3.2 Billion INR | -3504.524% |
| Strides Pharma Science Limited | 58.39 Billion INR | -97.757% |
| Venus Remedies Limited | 6.26 Billion INR | -1742.366% |
| Aarti Pharmalabs Limited | 25.82 Billion INR | -347.252% |
| Nectar Lifesciences Limited | 21.91 Billion INR | -427.075% |
| Shilpa Medicare Limited | 30.93 Billion INR | -273.351% |
| Aarti Drugs Limited | 24.32 Billion INR | -374.786% |
| IOL Chemicals and Pharmaceuticals Limited | 22.44 Billion INR | -414.547% |
| Suven Life Sciences Limited | 2.84 Billion INR | -3953.489% |
| Ind-Swift Limited | 6.54 Billion INR | -1664.554% |
| Valiant Laboratories Limited | 3.42 Billion INR | -3269.982% |
| J. B. Chemicals & Pharmaceuticals Limited | 39.94 Billion INR | -189.137% |
| Solara Active Pharma Sciences Limited | 23.5 Billion INR | -391.225% |
| Themis Medicare Limited | 5.66 Billion INR | -1938.871% |
| Hikal Limited | 24.87 Billion INR | -364.329% |
| Torrent Pharmaceuticals Limited | 150.61 Billion INR | 23.322% |
| Sequent Scientific Limited | 15.4 Billion INR | -649.716% |
| Novartis India Limited | 9.24 Billion INR | -1148.581% |
| Wockhardt Limited | 76.49 Billion INR | -50.981% |
| Biofil Chemicals and Pharmaceuticals Limited | 470.82 Million INR | -24428.118% |
| Neuland Laboratories Limited | 18.32 Billion INR | -530.184% |
| Morepen Laboratories Limited | 12.93 Billion INR | -793.014% |
| Kilitch Drugs (India) Limited | 2.4 Billion INR | -4710.64% |
| Mangalam Drugs & Organics Limited | 3.33 Billion INR | -3363.606% |